Tavneos (Avacopan)

Brand Options

arrow pointer

Brand Name : Tavneos

Marketing Authorization Holder : Amgen

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Tavneos

Save with Tavneos from Insulinhub - product of Europe

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manfactured for Europe at:Vifor France 100–101 Terrasse Boieldieu Tour Franklin La Défense 8 92042 Paris La Défense Cedex France

Information about Tavneos (Avacopan)

  • Tavneos is the brand name for avacopan, an oral medication used primarily in the treatment of autoimmune diseases. It is a selective inhibitor of the C5a receptor, which plays a key role in inflammation and immune cell recruitment. By blocking this receptor, Tavneos helps to reduce the activity of the immune system and control the inflammation associated with certain conditions.

Product Highlights

  • Tavneos is approved for the treatment of AAV, a group of diseases characterized by inflammation of small blood vessels, often affecting organs like the kidneys, lungs, and upper respiratory tract.
  • Tavneos can be used to reduce the reliance on corticosteroids for managing AAV, potentially minimizing steroid-related side effects.

Key Ingredient

  • Avacopan

Key Benefits

  • By inhibiting the C5a receptor, Tavneos reduces the recruitment of inflammatory immune cells to areas of disease activity, thereby controlling inflammation.
  • Tavneos can help reduce the need for corticosteroids in patients with AAV, which helps minimize the potential side effects of long-term steroid use, such as weight gain, bone thinning, and increased infection risk.
  • Clinical studies have shown that Tavneos, when used in combination with standard immunosuppressive treatments, can improve disease outcomes in patients with AAV, including reducing the severity of flare-ups and promoting long-term disease control.

Direction of Use

  • Tavneos is taken orally in the form of capsules, usually once or twice daily depending on the prescribed regimen.
  • The usual dose for AAV is 30 mg twice daily, but the exact dose and schedule should be followed as directed by the prescribing healthcare provider.
  • It is important to take Tavneos consistently and exactly as prescribed to ensure optimal effectiveness.

Safety Concerns

  • Tavneos may increase the risk of infections, particularly respiratory and opportunistic infections, due to its immune-modulating effects.
  • Tavneos can cause liver enzyme elevations. Regular monitoring of liver function is recommended during treatment.
  • Kidney function should be regularly monitored, especially in patients with pre-existing kidney conditions, as AAV commonly affects the kidneys.
  • Though rare, some individuals may experience hypersensitivity reactions (e.g., rash, fever, or swelling). Any signs of an allergic reaction should be reported to a healthcare provider immediately.
  • Tavneos is not recommended during pregnancy unless the potential benefits outweigh the risks. Its safety in breastfeeding is also not well established.

Avoid Tavneos (Avacopan) If

  • Tavneos should be avoided in patients with severe liver impairment or active liver disease due to potential liver toxicity.
  • Tavneos should be avoided during pregnancy unless absolutely necessary, as it is classified as a pregnancy Category C drug, meaning it could harm the fetus.
  • Avoid using Tavneos in patients with active or severe infections, particularly those that could be worsened by immune system suppression.
  • Tavneos should not be used in individuals who have a known hypersensitivity or allergy to avacopan or any of its ingredients.


Image Image Image Image